featured
ESMO 2021: VESPER Trial Indicates Neoadjuvant Dose-Dense MVAC May be Practice-Impacting in Muscle Invasive Bladder Cancer.
Dose-dense MVAC did not improve 3-year PFS in all peri-operative therapy patients, but did improve PFS as neoadjuvant therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.